Thank you to our speakers, sponsors, and delegates who joined us at the 7th Obesity & NASH Drug Development Summit!

If you are interested in the 2024 event, please get in touch at

Navigate End-To-End Strategic Updates in NASH & Obesity to Define the Evolving Competitive Landscape in Metabolic Disorders

Returning in September 2024

Welcome to the 7th Obesity & NASH Drug Development 2023 Summit

Eli Lilly’s ‘triple G’ drug retatrutide has galvanized the metabolic field to boost investment in the game-changing obesity drug revolution. With up to 24% weight loss, a new record for the obesity field has been set and the time to get ahead of the curve is now.

In parallel, we’re witnessing history being made with the world’s first approved NASH treatment potentially being right around the corner with Madrigal’s THR β-selective agonist, marking this year a pivotal time for the metabolic field to forever elevate the approach towards drug development and overcome regulatory barriers.

The 7th Obesity & NASH Drug Development Summit Reunited metabolic experts to enable the assessment of the competitive landscape . Participants had the opportunity to:

  • better understand the state of blood based, imaging and predictive biomarkers to meet primary endpoints and attain regulatory approval
  • explore GLP-1 RAs in a new light with FGF21, GIP, Amylin, glucagon receptors and more to lead to better therapeutic profile
  • ascertain a safety profile and successfully demonstrate efficacy in combination therapy to accurately assess multiple mechanisms of action

With 160+ experts from Eli Lilly, Novo Nordisk, Madrigal, Akero, Gilead, Pfizer, AstraZeneca, Gilead, Inventiva, and many more, participants discussed sustainable weight-loss drugs and the route towards the first approval in NASH.

2023 Expert Speaker Faculty:

Erik Tillman

Associate Director - Translational Biology & Pharmacology

Akero Therapeutics

Jingye Zhou

Co-Founder & Chief Executive Officer


Kevin Hart

Associate Director & Fellow - Scientific, Research


Mark Hartman

Vice President, Medical, NASH/Obesity

Eli Lilly & Co.

Mary Haas

Senior Manager, Cardiovascular Metabolic & Skeletal Disease Genetics

Regeneron Pharmaceuticals Inc

Noah Davidsohn

Chief Scientific Officer

Rejuvenate Bio

Rebecca Taub

Founder, Chief Executive & Medical Officer, President - Research & Development

Madrigal Pharmaceuticals

Zhao (Joe) Wang

Regulatory Affairs Director, Late CVRM


2023 Attending Companies Included:

34076 Who's Attending (800 x 200 px) (500 x 100 px) (3)

What do GLP-1 agonists mean for obesity and NASH treatment?

Tien Lee, CEO of Aardvark Therapeutics shares their insights.


Why Was the Industry Excited to Attend:

“Quality of the speakers and the subject matter was outstanding. The attendees were very interactive and discussions in the meeting and during the breaks were excellent”

Cyta Therapeutics

“Presentations were very informative, cutting edge and "timely", representing the current state of R&D in the Obesity and NASH field, with excellent Q&A”


“Fantastic speakers and audience participation”

Myovant Sciences

“Looking forward to sharing our work and areas of interest with academic and industry colleagues to collectively discuss, identify, and solve major problems in the field to bring cutting edge treatments to patients” 


“I appreciate the focus on drug development with active participation of industry experts. With this focus, the learning is different from what one gets at meetings run by scientific societies and offers great networking opportunities” 

Eli Lilly

Other Events In The Series Include:

2023 Partners:

antaros logo
repair biotech
nordic bioscience
Screenshot 2023-10-26 123334
AGA Horizontal Logo - Color
logo echosens and claim_gradient (1)